Randy J Georgemiller, PHD | |
300 E Hospital Rd, Room 13a-10, Fort Gordon, GA 30905-5650 | |
(706) 787-3143 | |
Not Available |
Full Name | Randy J Georgemiller |
---|---|
Gender | Male |
Speciality | Clinical Neuropsychologist |
Location | 300 E Hospital Rd, Fort Gordon, Georgia |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1205904950 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
103TC0700X | Psychologist - Clinical | 071-003110 (Illinois) | Secondary |
103G00000X | Clinical Neuropsychologist | PSY003859 (Georgia) | Primary |
Mailing Address | Practice Location Address |
---|---|
Randy J Georgemiller, PHD 300 E Hospital Rd, Room 13a-10, Ft Gordon, GA 30905-5650 Ph: (706) 787-3143 | Randy J Georgemiller, PHD 300 E Hospital Rd, Room 13a-10, Fort Gordon, GA 30905-5650 Ph: (706) 787-3143 |
News Archive
Portico Systems, the leader in Integrated Provider Management solutions, was chosen by IDC Health Insights to be the focus for a special report that provides a detailed view into Portico's market position, provider management software and service capabilities and future strategic direction. Additionally, the report provides analyst commentary on why assets such as Portico are necessary for successful reform change.
Twitter and other social media should be better utilized to convey public health messages, especially to young adults, according to a new analysis by researchers at UC San Francisco.
Solix Algredients, Inc. has introduced Solasta Astaxanthin to the B2B ingredients marketplace. Solasta is a natural astaxanthin extract produced from the microalga Haematococcus pluvialis, the richest natural source of the antioxidant. Research has shown that algal astaxanthin has superior antioxidant activity compared to other well-known antioxidants.
Researchers from the UK and Germany recently reported a comprehensive characterization of the SARS-CoV-2 response of human nasal epithelial cells, revealing a response dominated by IFN-I/IIIs. Also, recombinant IFN-I/III treatment was found to efficiently block the replication of SARS-CoV-2, which suggests that mucosal delivery of IFNs may be a good strategy for prophylaxis post-exposure.
› Verified 4 days ago